Jul 29, 2021 8:00am EDT Sapience Therapeutics Commences Dosing in Final Dose-Escalation Cohort of Ongoing Phase 1-2 Study of ST101
Jul 15, 2021 8:00am EDT Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect
May 27, 2021 4:30pm EDT Sapience Therapeutics Enters Into Collaboration with National Cancer Institute (NCI) to Study ST101 Response in Specialized Tumor Models
May 18, 2021 4:05pm EDT Sapience Therapeutics Awarded SBIR Phase I Grant from National Institute of Allergy and Infectious Diseases
Apr 06, 2021 4:05pm EDT Sapience Therapeutics Announces Multiple Posters, Including Late-Breaker, at the American Association for Cancer Research (AACR) Annual Meeting 2021
Mar 04, 2021 8:30am EST Sapience Therapeutics to Present at the Upcoming 2021 Spring Private Company Showcase hosted by Credit Suisse, Solebury Trout, and Cooley
